The rarity of patients with Leigh’s Syndrome results in a paucity of information regarding anesthesia administration and management, particularly for those patients who exhibit mitochondrial disorders that involve multi organ systems. Anesthetic management depends on the assessment of these systems prior to any surgical procedure and close observation following surgery. Reports of complications using volatile agents in patients with mitochondrial defects are mixed. In a 2006 animal study, Bains and colleagues (
3) suggested that volatile agents could becontra indicated in patients with mitochondrial defects. Conversely, a study by Morgan et al. (
4) suggested no contraindications in patients with mitochondrial dysfunction; the study of 16 patients included 1 diagnosed with Leigh’s Syndrome. Although malignant hyperthermia has not been reported with Leigh’s syndrome, it may be best to avoid triggering agents as other myopathic conditions with susceptibility for malignant hyperthermia may be misdiagnosed as Leigh’s syndrome. In this case specifically, the patient had a relative with malignant hyperthermia and this further limits the anesthetics that can be used. Additionally, close patient monitoring following surgery is important to avoid respiratory failure.
In our case, we chose to use dexmedetomidine with remifentanil for the induction and maintenance of anesthesia for its rapid recovery profile, with limited postoperative central nervous system and respiratory depression and safety in patients at risk for malignant hyperthermia. Dexmedetomidine and remifentanil infusion provided a good combination of sedation and analgesia which can be used in other procedures that require cardiac stability. We recommend avoiding circumstances that place a metabolic burden on these patients like prolonged fasting, hypoglycemia, postoperative nausea and vomiting, hypothermia with resulting shivering, prolonged tourniquets, acidosis, and hypovolemia.